Arcutis Biotherapeutics
ARQTClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$81.50M $99.22M $376.07M $105.40M
Cost of Revenue / Sales
($7.49M) ($8.69M) ($36.70M) ($9.78M)
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($19.45M) ($19.60M) ($77.05M) ($30.63M)
Selling, General & Administrative (SG&A)
($69.17M) ($62.40M) ($274.55M) ($74.08M)
Operating Income / (Loss)
($14.61M) $8.53M ($12.23M) ($9.09M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
($3.03M) ($3.07M) ($12.08M) ($4.37M)
Other Non-Operating Income / (Expense)
$2.10M $2.04M $0.44M ($0.02M)
Income Tax Provision / (Benefit)
$0.34M $0.08M $1.17M $0.09M
NET INCOME / (NET LOSS)
($15.89M) $7.41M ($16.14M) ($11.29M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$72.7M$47.1M$42.9M$34.8M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$72.7M$47.1M$42.9M$34.8M
Accounts Receivable, Net
$106.7M$115.1M$146.2M$144.4M
Prepaid Expenses & Other Current Assets
$18.6M$20.3M$21.1M$32.0M
Total Current Assets
$332.8M$349.2M$411.2M$438.1M
Property, Plant and Equipment, Net
$1.4M$1.2M$1.0M$1.0M
Intangibles & Other Non-Current Assets
$15.9M$15.4M$14.8M$14.3M
TOTAL CONSOLIDATED ASSETS
$352.4M$371.0M$433.0M$460.0M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$15.1M$5.8M$12.5M$18.3M
Accrued Expenses & Clinical Liabilities
$87.9M$93.0M$116.3M$137.0M
Total Current Liabilities
$103.9M$99.8M$129.8M$163.2M
Long-Term Corporate Debt Balances
$107.0M$107.5M$108.0M$101.5M
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$2.5M$5.6M$5.7M$5.7M
Total Liabilities Block
$213.5M$212.9M$243.5M$270.4M
Total Stockholders' Equity
$139.0M$158.1M$189.5M$189.6M
TOTAL LIABILITIES & EQUITY
$352.4M$371.0M$433.0M$460.0M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
3.20x 3.50x 3.17x 2.68x
R&D Expenditure Flow
$37.0M$56.6M$77.1M$30.6M
Net Income / (Loss)
($15.89M) $7.41M ($16.14M) ($11.29M)
Depreciation & Amortization
— — $0.70M —
Stock-Based Compensation
$20.27M $30.30M $40.36M $10.69M
Change in Accounts Receivable
$33.62M $42.05M $73.16M ($1.85M)
Change in Prepaid Assets / Expenses
($1.02M) $0.74M $2.01M $11.73M
Change in Payables & Clinical Accruals
$0.86M ($8.43M) ($1.69M) $5.61M
Other Operating Source / (Use) Changes
($67.90M) ($103.89M) ($104.02M) ($12.64M)
Net Cash from Operating Activities
($30.06M) ($31.81M) ($5.63M) $2.24M
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.69M) ($0.69M) ($0.69M) $0.00M
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
$129.12M $172.42M — —
Net Cash from Investing Activities
$29.17M $3.93M ($30.25M) ($11.33M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — $0.00M —
Proceeds from Issuing Stock / ATM Options
$0.00M $0.00M $0.00M —
Net Cash from Financing Activities
$1.77M $3.25M $6.97M $1.07M
NET CONSOLIDATED CHANGE IN CASH
$1.10M ($24.52M) ($28.74M) ($8.14M)
Clinical Trials Registry
Registry ID
Phase / Asset
Status
NCT02187250
P-4 — ARQ-151
completed
NCT01664624
P-1 — ARQ-151
completed
NCT00242294
P-2 — ARQ-151
completed
NCT04108377
P-1 — ARQ-151
terminated
NCT04211389
P-3 — ARQ-151
completed
NCT04800172
P-3 — ARQ-151
completed
NCT04973228
P-3 — ARQ-151
completed
NCT00163527
P-3 — ARQ-151
completed
NCT07453602
P-1 — ARQ-234
recruiting